Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT00853372
First received: February 26, 2009
Last updated: September 5, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: March 2017
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: November 2, 2015
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):